.png)
Key Messages:
Antimicrobial Resistance is a growing health concern, both across the globe where it is attributed with 1.27 million deaths each year and associated with 4.95 million each year, and in Sweden with around 330 attributable deaths and over 1,500 associated deaths each year.
The pipeline of new antimicrobials has grown increasingly thin and is inadequate to provide the vital new medicines that are needed to treat drug-resistant infections.
In recent years, Sweden has successfully demonstrated how a revenue guarantee can be used to secure access to existing antimicrobials. By working to expand the existing revenue guarantee model for antibiotics to incentivise innovation, both within Sweden and through collaboration with Nordic, European, and global partners, Sweden can play a pivotal role in revitalising the antimicrobial pipeline and ensuring patients have access to effective treatments.
Based on the disease burden attributable to AMR, we model that Sweden’s contribution to financing a global pull incentive scheme aimed at incentivising the development of and securing access to 18 new antimicrobials over 30 years would conservatively:
Save over 170 lives, generate €214 million in total benefits and yield an ROI of 2.1:1 over a 10-year period in Sweden.
Save at least 2,700 lives, generate €3.35 billion in total benefits and yield an ROI of 10.1:1 over a 30-year period in Sweden.
Additionally, Sweden’s contribution to the pull incentive scheme would represent saving over 5,900 lives in 10 years and over 113,000 lives in 30 years globally, through the new antimicrobials developed from the incentive program.
Such a scheme would cost Sweden an estimated €3.8 million per drug per year over a 10 year period, representing its “fair share” of a pull incentive basket funded by the G7 and the EU.
Comments